75 citations
,
February 2016 in “The Journal of Sexual Medicine” Androgens play a role in female sexual function, and testosterone therapy can help women with low sexual desire, but more research is needed on treatments and long-term safety.
31 citations
,
January 2017 in “Advances in Experimental Medicine and Biology” Low testosterone and 5α-reductase inhibitors can harm men's metabolic and sexual health; testosterone therapy may help, but discussing 5α-RIs' side effects is important.
70 citations
,
September 2017 in “Expert opinion on therapeutic patents” The review suggests that while many AKR1C3 inhibitors show promise for treating certain cancers, more research is needed to confirm their effectiveness in humans.
45 citations
,
August 2010 in “Hormone Molecular Biology and Clinical Investigation” Type 3 5α-reductase is more common and finasteride and dutasteride strongly inhibit it.
3 citations
,
December 2021 in “Physiological Research” Low testosterone may increase COVID-19 severity in men.
4 citations
,
March 2022 in “Journal of Infection” Anti-androgen therapy might help protect against COVID-19 infection and reduce death risk.
54 citations
,
January 2021 in “Biophysics Reports” Cell-based screening methods are useful and cost-effective for drug discovery but have pros and cons.
10 citations
,
October 2012 in “Andrology” Prostate cancer can progress even with low testosterone due to internal hormone production in the tumor.
February 2023 in “Vaccines” COVID-19 may harm male reproductive health and lower testosterone levels, potentially affecting fertility and causing erectile dysfunction. More research is needed.
18 citations
,
June 2021 in “Endocrinology” Anti-androgens might help reduce COVID-19 severity in men.
25 citations
,
February 2022 in “JAAD International” Some COVID-19 patients lose hair, with the most common type linked to male hormones and possibly increasing the risk of severe illness.
23 citations
,
September 2020 in “BMC Cancer” 5α-reductase inhibitors may lower the risk of death from bladder cancer.
4 citations
,
June 2023 in “Frontiers in Aging” Improving blood flow and oxygen levels in middle age may help prevent age-related diseases.
2 citations
,
February 2023 in “BJUI” Urologists should monitor mental health in patients taking finasteride due to potential links to suicidal thoughts, adjusting dosage or stopping use if necessary. More research is needed to confirm if finasteride causes these thoughts.
4 citations
,
October 2020 in “Actas Dermo-Sifiliográficas” Common dermatology drugs were considered but are controversial for COVID-19 treatment.
September 2012 in “African Journal of Urology” Testosterone replacement therapy improves libido, mood, muscle strength, and bone density in men with Testosterone Deficiency Syndrome.
July 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” The structure of SRD5A reveals how it reduces steroids, aiding drug design for related health conditions.
June 2016 in “Annals of the rheumatic diseases” Methotrexate is effective for treating rheumatoid arthritis but requires regular monitoring.
October 2022 in “Journal of experimental and clinical medicine” Repurposing existing drugs for COVID-19 shows promise but requires more research to confirm effectiveness.
September 2020 in “arXiv (Cornell University)” Some existing drugs and natural products might work against COVID-19 by targeting the virus's main protease.
11 citations
,
September 1997 in “Archives of Dermatology” Reduced androgens linked to kinky hair disorder and hair loss; 5a-reductase inhibitors may help.
August 2025 in “Therapeutics” Low-dose DMSO may help treat castration-resistant prostate cancer by reducing key cancer cell receptors.
Androgen suppression therapy (AST) doesn't significantly lower bladder cancer risk, but using finasteride, a type of AST, might decrease the risk. AST also lessens the chance of cancer coming back but doesn't really affect survival rates. More research is needed to understand AST's benefits for different bladder cancers.
August 2025 in “ACS Omega” New compounds show promise as nonsteroidal treatments for hair loss.
56 citations
,
December 2011 in “The Plant Journal” AGD1 is important for root hair development in Arabidopsis, working with phosphoinositide signaling and the actin cytoskeleton.
11 citations
,
June 2017 in “Journal of cell science” AGD1's PH domain is essential for its role in root hair growth and polarity.
January 2026 in “Journal of Materials Chemistry B” TA-Ado effectively promotes hair growth and reduces hair loss.
May 2018 in “International Society of Hair Restoration Surgery” March 2018 in “International Society of Hair Restoration Surgery” January 2018 in “International Society of Hair Restoration Surgery”